We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Positive Results Seen in Juvenile Diabetes Vaccine Study

Positive Results Seen in Juvenile Diabetes Vaccine Study

October 14, 2008

Diamyd Medical’s experimental vaccine Diamyd Type 1, used to treat Type 1 diabetes soon after diagnosis in patients age 10–18 years, slowed the loss of function in residual beta cells that produce insulin in the pancreas.

The effect, which was not a primary endpoint in the Phase II trial, lasted as long as 30 months and “may contribute to the preservation of residual insulin secretion in patients with recent-onset type 1 diabetes, although it did not change the insulin requirement,” according to a study published in The New England Journal of Medicine.

The article concludes that the results from the 70 patients in the study “provide preliminary proof of concept” for the vaccine.

Upcoming Events

  • 28Jun

    The Prediction Impact: Reduce Compliance Risks with Novel AI and ML Technology

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • SI-BONE Gets FDA Clearance for Its iFuse Bedrock Granite for Spinal Treatment

  • Sanofi and GSK Present Promising Data for Bivalent COVID-19 Vaccine

  • Aurora Spine Gets FDA Clearance for Spinal Fusion Device

  • Rexulti Shows Efficacy in Reducing Agitation in Alzheimer’s Patients

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing